Breast Cancer Clinical Trial
Breast, Omega 3 Free Fatty Acid, Ph 0
Summary
Assess the impact of dietary omega 3 free fatty acids breast cancer patients.
Full Description
Prospective, single arm, short term study with correlative biomarker endpoints. Two hundred (200) newly diagnosed breast cancer patients will be recruited to participate in a short term (30 day) Phase 0 biomarker evaluation study prior to surgical resection. Patients will be receive fish Oil (Omega-3 FFAs, 2700 mg by mouth twice daily).
Eligibility Criteria
Inclusion Criteria:
At least 18 years of age
ECOG ≤2
Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee
Consented for tissue collection on CTRC repository 07-32
Exclusion Criteria:
Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)
Chronic use of NSAIDs or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)
Any NSAIDs or omega-3 free fatty acid supplementation within the last 14 days
History of medical noncompliance
Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Antonio Texas, 78229, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.